Obesity Market Snapshot: Marketing Partners Giving Obesity The Slow Goodbye
Executive Summary
Takeda's split from Contrave partner Orexigen may be followed by Eisai leaving Arena; the big pharma is already pulling back reps from Belviq, though Arena has high hopes for a new extended-release formulation.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.